Spiriva Safety Data Remains Key Hurdle For Respimat Inhaler
This article was originally published in The Pink Sheet Daily
Executive Summary
Conflicting findings to be discussed at Boehringer Ingelheim’s Aug. 14 advisory committee review of its tiotropium spray as FDA reviewers offer varying opinions on impact of new trial data.